MedTrace Logo

A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer

NCT02448173 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 550

Last updated 2026-02-02

No results posted yet for this study

Summary

OncoVAX® is the first cancer therapy that both prevents cancer recurrence and

addresses the diversity of cancer cells. In this pivotal randomized, multicenter Phase

IIIb study in patients with Stage II colon cancer, OncoVAX is designed to use a patient's

own cancer cells to mobilize the body's immune system to prevent the return of colon

cancer following surgery.

Conditions

  • Stage II Colon Cancer

Interventions

BIOLOGICAL

OncoVAX and Surgery

OncoVAX is comprised of sterile, live but non-dividing tumor cells obtained following standard-of-care surgical tumor resection for Stage II colon cancer

PROCEDURE

Surgery

Surgical resection of Stage II colon cancer

Sponsors & Collaborators

  • Vaccinogen Inc

    lead INDUSTRY

Principal Investigators

  • Michael G Hanna, Jr, PhD · Vaccinogen Inc

  • Herbert C. Hoover, MD · Vaccinogen Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2031-08-31
Completion
2033-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02448173 on ClinicalTrials.gov